Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: Evidence for the critical function of multimerization

Virology

Volumn 363, Issue 1, 2007, Pages 59-68

  Denis, Jérôme ^a   Majeau, Nathalie ^a   Acosta Ramirez, Elizabeth ^a,b   Savard, Christian ^a   Bedard, Marie Claude ^a   Simard, Sabrina ^a   Lecours, Katia ^c   Bolduc, Marilène ^a   Pare, Christine ^a   Willems, Bernard ^d   Shoukry, Naglaa ^d   Tessier, Philippe ^a   Lacasse, Patrick ^e   Lamarre, Alain ^e   Lapointe, Réjean ^f   Lopez Macias, Constantino ^b   Leclerc, Denis ^a  

^a LAVAL UNIVERSITY   (Canada)

^b HOSPITAL DE ESPECIALIDADES   (Mexico)

^c Centre de Recherche sur la fonction   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

^e INRS INSTITUT ARMAND FRAPPIER   (Canada)

^f NOTRE DAME HOSPITAL   (Canada)

Author keywords

Chimeric plant virus; Epitope carrier; Vaccination; Virus like particles (VLPs)

Indexed keywords

CAPSID PROTEIN; EPITOPE; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; MONOMER; PAPAYA MOSAIC VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW; CONTROLLED STUDY; DRUG MECHANISM; HEPATITIS C; HEPATITIS C VIRUS; HUMORAL IMMUNITY; IMMUNOGENICITY; MOSAICISM; MOUSE; NONHUMAN; PAPAYA; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN ENGINEERING; TH1 CELL; TH2 CELL; VIRUS LIKE AGENT;

ANIMALS; BONE MARROW CELLS; CAPSID PROTEINS; CARICA; DENDRITIC CELLS; EPITOPES; GENETIC ENGINEERING; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C ANTIGENS; HUMANS; MICE; MOSAIC VIRUSES; RNA; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

HEPATITIS C VIRUS; MIRIDAE; MUS; PAPAYA MOSAIC VIRUS;

EID: 34247846212     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.01.011     Document Type: Article

References (40)

1. Ada G. Vaccines and vaccination. N. Engl. J. Med. 345 14 (2001) 1042-1053
2. Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., and Zinkernagel R.M. The influence of antigen organization on B cell responsiveness. Science 262 5138 (1993) 1448-1451
3. Bachmann M.F., Hengartner H., and Zinkernagel R.M. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction?. Eur. J. Immunol. 25 12 (1995) 3445-3451
4. Baschong W., Hasler L., Haner M., Kistler J., and Aebi U. Repetitive versus monomeric antigen presentation: direct visualization of antibody affinity and specificity. J. Struct. Biol. 143 3 (2003) 258-262
5. Brewer J.M. (How) do aluminium adjuvants work?. Immunol. Lett. 102 1 (2006) 10-15
6. Brunswick M., Finkelman F.D., Highet P.F., Inman J.K., Dintzis H.M., and Mond J.J. Picogram quantities of anti-Ig antibodies coupled to dextran induce B cell proliferation. J. Immunol. 140 10 (1988) 3364-3372
7. Canizares M.C., Nicholson L., and Lomonossoff G.P. Use of viral vectors for vaccine production in plants. Immunol. Cell Biol. 83 3 (2005) 263-270
8. Chackerian B., Lowy D.R., and Schiller J.T. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 108 3 (2001) 415-423
9. Daar A.S., Thorsteinsdottir H., Martin D.K., Smith A.C., Nast S., and Singer P.A. Top ten biotechnologies for improving health in developing countries. Nat. Genet. 32 2 (2002) 229-232
10. Dintzis H.M., Dintzis R.Z., and Vogelstein B. Molecular determinants of immunogenicity: the immuno model of immune response. Proc. Natl. Acad. Sci. U.S.A. 73 10 (1976) 3671-3675
11. Erickson J.W., Bancroft J.B., and Horne R.W. The assembly of papaya mosaic virus protein. Virology 72 2 (1976) 514-517
12. Fagan E.A., Tolley P., Smith H.M., Peters M.P., Coleman J., Elliott P., Williams R., and Eddleston A.L. Hepatitis B vaccine: immunogenicity and follow-up including two year booster doses in high-risk health care personnel in a London teaching hospital. J. Med. Virol. 21 1 (1987) 49-56
13. Feldmann M., and Easten A. The relationship between antigenic structure and the requirement for thymus-derived cells in the immune response. J. Exp. Med. 134 1 (1971) 103-119
14. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., McKenzie I.F., and Plebanski M. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173 5 (2004) 3148-3154
15. Gamvrellis A., Leong D., Hanley J.C., Xiang S.D., Mottram P., and Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunol. Cell Biol. 82 5 (2004) 506-516
16. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., Zahaf T., Innis B., Naud P., De Carvalho N.S., Roteli-Martins C.M., Teixeira J., Blatter M.M., Korn A.P., Quint W., and Dubin G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
17. Houghton M., and Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 436 7053 (2005) 961-966
18. Jegerlehner A., Tissot A., Lechner F., Sebbel P., Erdmann I., Kundig T., Bachi T., Storni T., Jennings G., Pumpens P., Renner W.A., and Bachmann M.F. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20 25-26 (2002) 3104-3112
19. Justewicz D.M., Doherty P.C., and Webster R.G. The B-cell response in lymphoid tissue of mice immunized with various antigenic forms of the influenza virus hemagglutinin. J. Virol. 69 9 (1995) 5414-5421
20. Kariko K., Buckstein M., Ni H., and Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23 2 (2005) 165-175
21. Lechner S., Rispeter K., Meisel H., Kraas W., Jung G., Roggendorf M., and Zibert A. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1. Virology 243 2 (1998) 313-321
22. Leclerc D., Burri L., Kajava A.V., Mougeot J.L., Hess D., Lustig A., Kleemann G., and Hohn T. The open reading frame III product of cauliflower mosaic virus forms a tetramer through a N-terminal coiled-coil. J. Biol. Chem. 273 44 (1998) 29015-29021
23. Leclerc, D., Beauseigle, D., Denis, J., Morin, H., Pare, C., Lamarre, A., Lapointe, R., in press. Proteasome-independent MHC class I cross-presentation mediated by papaya mosaic virus-like particles leads to the expansion of specific human T cells. J Virol. (in press online)
24. Lecours K., Tremblay M.H., Gagne M.E., Gagne S.M., and Leclerc D. Purification and biochemical characterization of a monomeric form of papaya mosaic potexvirus coat protein. Protein Expr. Purif. (2005)
25. Lenz P., Thompson C.D., Day P.M., Bacot S.M., Lowy D.R., and Schiller J.T. Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin. Immunol. 106 3 (2003) 231-237
26. Loor F. Comparative immunogenicities of tobacco mosaic virus, protein subunits, and reaggregated protein subunits. Virology 33 2 (1967) 215-220
27. Marusic C., Rizza P., Lattanzi L., Mancini C., Spada M., Belardelli F., Benvenuto E., and Capone I. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J. Virol. 75 18 (2001) 8434-8439
28. McInerney T.L., Brennan F.R., Jones T.D., and Dimmock N.J. Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide. Vaccine 17 11-12 (1999) 1359-1368
29. Milich D.R., and McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 234 4782 (1986) 1398-1401
30. Milich D.R., Chen M., Schodel F., Peterson D.L., Jones J.E., and Hughes J.L. Role of B cells in antigen presentation of the hepatitis B core. Proc. Natl. Acad. Sci. U.S.A. 94 26 (1997) 14648-14653
31. Mond J.J., Lees A., and Snapper C.M. T cell-independent antigens type 2. Annu. Rev. Immunol. 13 (1995) 655-692
32. Nattermann J., Schneiders A.M., Leifeld L., Langhans B., Schulz M., Inchauspe G., Matz B., Brackmann H.H., Houghton M., Sauerbruch T., and Spengler U. Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC). J. Hepatol. 42 4 (2005) 499-504
33. Noad R., and Roy P. Virus-like particles as immunogens. Trends Microbiol. 11 9 (2003) 438-444
34. Piazzolla G., Nuzzaci M., Tortorella C., Panella E., Natilla A., Boscia D., De Stradis A., Piazzolla P., and Antonaci S. Immunogenic properties of a chimeric plant virus expressing a hepatitis C virus (HCV)-derived epitope: new prospects for an HCV vaccine. J. Clin. Immunol. 25 2 (2005) 142-152
35. Ruedl C., Storni T., Lechner F., Bachi T., and Bachmann M.F. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur. J. Immunol. 32 3 (2002) 818-825
36. Saini M., and Vrati S. A Japanese encephalitis virus peptide present on Johnson grass mosaic virus-like particles induces virus-neutralizing antibodies and protects mice against lethal challenge. J. Virol. 77 6 (2003) 3487-3494
37. Streatfield S.J., and Howard J.A. Plant-based vaccines. Int. J. Parasitol. 33 5-6 (2003) 479-493
38. Sugiyama T., Gursel M., Takeshita F., Coban C., Conover J., Kaisho T., Akira S., Klinman D.M., and Ishii K.J. CpG RNA: identification of novel single-stranded RNA that stimulates human CD14+CD11c+ monocytes. J. Immunol. 174 4 (2005) 2273-2279
39. Tremblay M.H., Majeau N., Gagne M.E., Lecours K., Morin H., Duvignaud J.B., Bolduc M., Chouinard N., Pare C., Gagne S., and Leclerc D. Effect of mutations K97A and E128A on RNA binding and self assembly of papaya mosaic potexvirus coat protein. FEBS J. 273 1 (2006) 14-25
40. Zinkernagel R.M. On natural and artificial vaccinations. Annu. Rev. Immunol. 21 (2003) 515-546